Diabetes research and clinical practiceFeb 9, 2019

Cigarette smoking, type 2 diabetes, and potential treatment with glucagon-like peptide-1 drugs for smokers with diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Apr 2, 2026

Abstract

Cigarette smoking in individuals with type 2 diabetes mellitus is associated with twice the likelihood of mortality and negative health outcomes.

Tobacco use disorder (TUD) significantly contributes to complications in type 2 diabetes mellitus (DM).
Persons with DM who regularly use tobacco products face increased health risks compared to non-smokers.
Epidemiological and preclinical biological evidence supports the interconnectedness of TUD and DM.
Glucagon-like peptide-1 (GLP-1) may serve as a potential treatment target for addressing TUD in smokers with DM.

Simplified

Tobacco use disorder (TUD), in particular cigarette smoking, contributes significantly to the macro- and micro-vascular complications of type 2 diabetes mellitus (DM). Persons with DM who regularly use tobacco products are twice as likely to experience mortality and negative health outcomes. Despite these risks, TUD remains prevalent in persons with DM. The objective of this integrative review is to summarize the relationship between TUD and DM based on epidemiological and preclinical biological evidence. We conclude with a review of the literature on the glucagon-like peptide-1 (GLP-1) as a potential treatment target for addressing comorbid TUD in smokers with DM.

Full Text

Full text is available at the source.

View Full Text ↗

Cigarette smoking, type 2 diabetes, and potential treatment with glucagon-like peptide-1 drugs for smokers with diabetes

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief